Eco Animal Health Group plc (AIM: EAH), a UK-headquartered global animal health company, hosted a Capital Markets Day on 11 November 2026 for institutional investors and analysts in the City of London. The event covered commercial strategy for its flagship products, business development priorities, and an R&D pipeline valuation framework. The company disclosed a risk-adjusted sum-of-the-parts enterprise valuation for its ECOVAXXIN® MS vaccine and broader R&D portfolio of approximately £100 million, alongside an indicative valuation range of £0 to £100 million for its early-stage PRRSvmAb asset, dependent on a near-term trial outcome.

Key Points

  • Eco Animal Health Group plc (AIM: EAH) is a leading global animal health company employing over 200 people worldwide
  • The company hosted a Capital Markets Day on 11 November 2026 in the City of London, with presentations from CEO David Hallas, CFO Chris Wilks, and other senior leaders
  • A risk-adjusted enterprise valuation of approximately £100m was disclosed for ECOVAXXIN® MS and the R&D portfolio; PRRSvmAb carries an indicative range of £0–£100m pending a key trial
  • Investors should watch for the CMD presentation materials, to be published at ecoanimalhealth.com/investors/reports-presentations following the event

Aivlosin® and ECOVAXXIN® MS Drive Commercial Strategy Discussion at CMD

Eco Animal Health's Capital Markets Day placed commercial strategy at its centre, with presentations addressing both Aivlosin® and ECOVAXXIN® MS. Aivlosin® is the company's proprietary lead antibiotic, used to treat respiratory and intestinal diseases in pigs and poultry and distributed across more than 70 markets globally. ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the European Union in July 2026, marking the first product to emerge from ECO's self-funded R&D pipeline. External testimonial from Eurovo, described as a leading European egg producer, was included via recorded interview to illustrate real-world experience with the vaccine.

ECO Discloses £100m Risk-Adjusted Valuation for Vaccine Pipeline Including PRRSvmAb Proof-of-Concept Asset

A central element of the Capital Markets Day was ECO's current valuation framework for its R&D portfolio. The announcement states a risk-adjusted sum-of-the-parts enterprise valuation of approximately £100 million for ECOVAXXIN® MS and the broader pipeline. Separately, PRRSvmAb, which is at proof-of-concept stage, carries an indicative valuation range of £0 to £100 million, with the outcome dependent on a key trial completing in the near term. The wide valuation range for PRRSvmAb reflects the binary nature of early-stage asset development, and investors may be watching trial progress closely as a potential value catalyst or risk event.

Vaxinano In-Licensing Agreement Adds Sheep Toxoplasmosis Vaccine Candidate to ECO's Pipeline

The CMD also highlighted ECO's August 2026 exclusive in-licensing agreement with Vaxinano, covering a sheep vaccine candidate targeting toxoplasmosis. Pr. Didier Betbeder, Chief Executive Officer of Vaxinano, contributed a recorded interview to the event. The agreement broadens ECO's pipeline beyond poultry into sheep health, consistent with the company's stated focus on prevention and vaccines as growth drivers. The company describes its R&D pipeline as self-funded, which the disclosure suggests reduces reliance on external capital for pipeline development and supports its stated positioning ahead of what management characterises as a next phase of growth.

CMD Presentations to Be Published Online; No New Material Disclosures Made at Event

ECO Animal Health confirmed in the announcement that the CMD presentations will be made available at ecoanimalhealth.com/investors/reports-presentations following the event, providing broader market access to the material covered. The company explicitly stated that, aside from the disclosed valuation framework and pipeline update, no new material disclosures would be made at the event. Chief Executive David Hallas was quoted in the announcement citing a resilient core business and a clear business development strategy as foundations for ECO's next phase. The company is headquartered in the UK with a global presence across more than 70 markets.